Piper Sandler analyst Christopher Donat maintains Enfusion (NYSE:ENFN) with a Overweight and lowers the price target from $15 to $12.
What’s The Fate Of FTX’s Deal To Purchase Bankrupt Crypto Lender Voyager for $1.4B?
Cryptocurrency lender Voyager Digital Ltd.